# Naproxen Sodium (2 x 220 mg) Fasted Comparative Bioavailability Study

> **NCT03167541** · PHASE1 · COMPLETED · sponsor: **Reckitt Benckiser Healthcare (UK) Limited** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Test
- **DRUG:** Reference

## Key facts

- **NCT ID:** NCT03167541
- **Lead sponsor:** Reckitt Benckiser Healthcare (UK) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-12
- **Primary completion:** 2016-12-02
- **Final completion:** 2016-12-02
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03167541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03167541, "Naproxen Sodium (2 x 220 mg) Fasted Comparative Bioavailability Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03167541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*